The $25M upfront provides near-term financial stability and de-risks Aligos' development program. Traders should monitor Amoytop's shareholder meeting outcome within 30 days as a key catalyst; if approved, this validates commercial momentum and could revalue Aligos' pipeline. Royalty potential and milestone exposure add significant optionality despite small market cap.
Price Chart
Executive Summary
Aligos Therapeutics announced an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic HBV in Greater China, receiving a $25M upfront payment and up to $420M in potential milestones, plus tiered high single-digit royalties. The deal extends Aligos' cash runway into Q4 2026 and leverages Amoytop's commercial strength in hepatology, though closing is conditional on Amoytop shareholder approval.
Key Financial Metrics
Key Facts
- Aligos receives $25M upfront from Amoytop for licensing pevifoscorvir sodium in Greater China
- Eligible for up to $420M in clinical, regulatory, and sales milestones
- Tiered high single-digit royalties on net sales in licensed territories
- Aligos retains global rights outside Greater China and right to conduct trials in the region
- Transaction closing contingent on Amoytop shareholder approval within 30 days
- Cash runway extended to Q4 2026 based on current operating plan
Financial Impact
$25M immediate cash inflow, up to $420M in potential future milestones, and ongoing royalty stream
Risk Factors
- Transaction may not close if Amoytop shareholders do not approve
- Geopolitical and regulatory risks in China, including NMPA approval uncertainty
- Future milestones are contingent on clinical and regulatory success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275110 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.65 (−15.61%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.65 (−14.36%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.65 (−16.96%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.65 (−39.30%) |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.65 (−37.33%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.65 (−33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers